BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33160684)

  • 21. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
    Zhang S; Wang X; Gu Z; Wang L
    Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YM155 induces EGFR suppression in pancreatic cancer cells.
    Na YS; Yang SJ; Kim SM; Jung KA; Moon JH; Shin JS; Yoon DH; Hong YS; Ryu MH; Lee JL; Lee JS; Kim TW
    PLoS One; 2012; 7(6):e38625. PubMed ID: 22723871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway.
    Sim MY; Yuen JSP; Go ML
    Sci Rep; 2018 Jul; 8(1):10289. PubMed ID: 29980758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
    Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
    BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
    Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
    Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
    Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C
    Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preliminary study of biological mechanism and apoptotic effect induced by YM155 in SUDHL-4 cell line].
    Liang W; Zhang WJ; Gao QM; Qin W; Lu HN; Huang BB; Xiu B; Liang AB
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(10):700-4. PubMed ID: 22781300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.
    Jane EP; Premkumar DR; Sutera PA; Cavaleri JM; Pollack IF
    Mol Carcinog; 2017 Apr; 56(4):1251-1265. PubMed ID: 27805285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.
    Tang H; Shao H; Yu C; Hou J
    Biochem Pharmacol; 2011 Nov; 82(9):1066-72. PubMed ID: 21784061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
    Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
    Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
    Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YM155 and BIRC5 downregulation induce genomic instability via autophagy-mediated ROS production and inhibition in DNA repair.
    Cheng SM; Lin TY; Chang YC; Lin IW; Leung E; Cheung CHA
    Pharmacol Res; 2021 Apr; 166():105474. PubMed ID: 33549731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells.
    Mondal A; Jia D; Bhatt V; Akel M; Roberge J; Guo JY; Langenfeld J
    Sci Rep; 2022 Jul; 12(1):13135. PubMed ID: 35908087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
    Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
    Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression.
    Chiou JT; Chang LS
    Apoptosis; 2024 Apr; 29(3-4):503-520. PubMed ID: 38066391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells.
    Feng W; Yoshida A; Ueda T
    Biochem Biophys Res Commun; 2013 May; 435(1):52-7. PubMed ID: 23618862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair.
    Hu S; Fu S; Xu X; Chen L; Xu J; Li B; Qu Y; Yu H; Lu S; Li W
    Cell Physiol Biochem; 2015; 37(3):1219-30. PubMed ID: 26418254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
    Nakamura N; Yamauchi T; Hiramoto M; Yuri M; Naito M; Takeuchi M; Yamanaka K; Kita A; Nakahara T; Kinoyama I; Matsuhisa A; Kaneko N; Koutoku H; Sasamata M; Yokota H; Kawabata S; Furuichi K
    Mol Cell Proteomics; 2012 Jul; 11(7):M111.013243. PubMed ID: 22442257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
    Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.